Among healthcare stocks, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has performed remarkably well over the past year, beating the benchmark NASDAQ Health Care Index (IXHC) by more than 35%.
The market seems excited about the company’s portfolio of innovative treatments for diseases of the central nervous system, which offers significant growth potential for the company.
However, as competition increases, there is uncertainty about the market prospects for one of the company’s products, and perhaps shareholders should consider holding this stock until the situation becomes a little clearer.
READ FULL ARTICLE HERE
